[{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Opaganib","moa":"SPHK2","graph1":"Oncology","graph2":"Phase II","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RedHill Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"University of Minnesota","sponsor":"Rising Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Minnesota","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"University of Minnesota \/ Rising Pharma","highestDevelopmentStatusID":"1","companyTruncated":"University of Minnesota \/ Rising Pharma"},{"orgOrder":0,"company":"Duke Clinical Research Institute","sponsor":"PCORI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Duke Clinical Research Institute","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Duke Clinical Research Institute \/ PCORI","highestDevelopmentStatusID":"10","companyTruncated":"Duke Clinical Research Institute \/ PCORI"},{"orgOrder":0,"company":"FibroGenesis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Fibroblast cells","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"FibroGenesis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"FibroGenesis \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"FibroGenesis \/ Not Applicable"},{"orgOrder":0,"company":"Rutgers Cancer Institute ","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Azithromycin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Rutgers Cancer Institute ","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rutgers Cancer Institute \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rutgers Cancer Institute \/ Not Applicable"},{"orgOrder":0,"company":"Lupus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Lupus Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lupus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Lupus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Not Applicable"},{"orgOrder":0,"company":"University of Utah Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"University of Utah Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of Utah Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"University of Utah Health \/ Not Applicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Opaganib","moa":"SPHK2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RedHill Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"University Hospitals Geneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University Hospitals Geneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"University Hospitals Geneva \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"University Hospitals Geneva \/ Not Applicable"},{"orgOrder":0,"company":"Royal Melbourne Hospital ","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Royal Melbourne Hospital ","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Royal Melbourne Hospital \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Royal Melbourne Hospital \/ Not Applicable"},{"orgOrder":0,"company":"CARE","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Imiquimod","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"CARE","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"CARE \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"CARE \/ Not Applicable"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Not Applicable"},{"orgOrder":0,"company":"Lundquist Institute ","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Azithromycin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Lundquist Institute ","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lundquist Institute \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Lundquist Institute \/ Not Applicable"},{"orgOrder":0,"company":"Columbia University Irving Medical Center ","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Columbia University Irving Medical Center ","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Columbia University Irving Medical Center \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Columbia University Irving Medical Center \/ Not Applicable"},{"orgOrder":0,"company":"IQVIA","sponsor":"Walter and Eliza Hall Institute of Medical Research","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"IQVIA \/ Walter and Eliza Hall Institute of Medical Research","highestDevelopmentStatusID":"9","companyTruncated":"IQVIA \/ Walter and Eliza Hall Institute of Medical Research"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"University of Oxford \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"University of Oxford \/ Not Applicable"},{"orgOrder":0,"company":"The AIDS Clinical Trials Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"The AIDS Clinical Trials Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"The AIDS Clinical Trials Group \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"The AIDS Clinical Trials Group \/ Not Applicable"},{"orgOrder":0,"company":"Progenabiome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Progenabiome","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Progenabiome \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Progenabiome \/ Not Applicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"World Health Organization","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"World Health Organization","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"World Health Organization \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"World Health Organization \/ Not Applicable"},{"orgOrder":0,"company":"ExeGi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Antibiotics","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"ExeGi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"ExeGi \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ExeGi \/ Not Applicable"},{"orgOrder":0,"company":"TLC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"TLC Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"TLC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"TLC Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"TLC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"TLC Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"TLC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"TLC Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Taiwan Liposome Company","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"ACE2","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Taiwan Liposome Company","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Taiwan Liposome Company \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Taiwan Liposome Company \/ Not Applicable"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Nicotinamide Riboside","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"ChromaDex, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ChromaDex, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Taiwan Liposome Company","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"ACE2","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Taiwan Liposome Company","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Taiwan Liposome Company \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Taiwan Liposome Company \/ Not Applicable"},{"orgOrder":0,"company":"Inserm","sponsor":"World Health Organization","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Inserm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Inserm \/ World Health Organization","highestDevelopmentStatusID":"10","companyTruncated":"Inserm \/ World Health Organization"},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Devimistat","moa":"Pyruvate dehydrogenase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cornerstone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cornerstone Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TLC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"ACE2","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"TLC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"TLC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TLC Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"ACE2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"tablet","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Not Applicable"},{"orgOrder":0,"company":"Drug for Neglected Diseases initiative","sponsor":"Inserm-ANRS","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Lopinavir","moa":"HIV-1 protease","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Drug for Neglected Diseases initiative","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Drug for Neglected Diseases initiative \/ Inserm-ANRS","highestDevelopmentStatusID":"10","companyTruncated":"Drug for Neglected Diseases initiative \/ Inserm-ANRS"},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Sara\u2019s Cure","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Devimistat","moa":"TCA cycle","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cornerstone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Sara\u2019s Cure","highestDevelopmentStatusID":"7","companyTruncated":"Cornerstone Pharmaceuticals \/ Sara\u2019s Cure"},{"orgOrder":0,"company":"University of Cologne","sponsor":"Apogenix","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR9","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"University of Cologne","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of Cologne \/ Apogenix","highestDevelopmentStatusID":"9","companyTruncated":"University of Cologne \/ Apogenix"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Nicotinamide Riboside","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"","sponsorNew":"ChromaDex, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ChromaDex, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Codebase","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Codebase","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Codebase \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Codebase \/ Not Applicable"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Incannex Healthcare \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Incannex Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Incannex Healthcare \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Incannex Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Incannex Healthcare \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Incannex Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Incannex Healthcare \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Incannex Healthcare \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals for Hydroxychloroquine Sulfate
Details :
IHL-675A is Incannex’s proprietary combination product containing cannabidiol (‘CBD’) and hydroxychloroquine sulfate (‘HCQ’) for treatment of inflammatory disorders including rheumatoid arthritis.
Details :
IHL-675A is Incannex’s proprietary combination product containing cannabidiol (‘CBD’) and hydroxychloroquine sulfate (‘HCQ’) for treatment of inflammatory disorders including rheumatoid arthritis.
Details :
IHL-675A is a fixed dose combination of cannabidiol and hydroxychloroquine. It is being investigated for rheumatoid arthritis, inflammatory bowel disease and lung inflammation.
Details :
IHL-675A is a combination cannabinoid drug comprising cannabidiol ('CBD') and hydroxychloroquine ('HCQ') in a fixed dose combination,synergistically to inhibit production of key inflammatory cytokines.
Details :
Codebase Ventures provided an update on the continued development of its proposed transdermal delivery technology for hydroxychloroquine (HCQ). The drug has been approved by the USFDA as a treatment against malaria, lupus, and rheumatoid arthritis.
Details :
The Phase 2 study reported a reduction in liver fat and inflammatory markers in patients with non-alcoholic fatty liver disease (NAFLD) when receiving a nutritional protocol including nicotinamide riboside (NR), L-serine, N-acetyl-L-cysteine (NAC), and L...
Details :
ACOVACT is a randomised, controlled, multi-centre, open-label clinical trial sponsored by MedUni Vienna. Within ACOVACT, different treatments for COVID-19 are compared to one another. The trial will evaluate Fas ligand blocker asunercept.
Details :
Rafael Pharmaceuticals will initiate a Phase 2 clinical trial of CPI-613®(devimistat) in combination with hydroxychloroquine in patients with clear cell sarcoma of soft tissue, in partnership with Sara’s Cure and Sarcoma Alliance for Research through ...
Details :
The trial will begin testing, against a control arm, the HIV antiretroviral combination lopinavir/ritonavir with a loaded dose and the malaria drug hydroxychloroquine, which remains the standard of care for COVID-19 today in numerous African countries.
Details :
The finding suggest that hydroxychloroquine is not effective for the treatment of COVID-19 was consistent across patient subgroups and for all evaluated outcomes, including clinical status, mortality, organ failures, duration of oxygen use, and hospital ...